Want to see GB:PRM full AI Analyst Report?
Top Page
Proteome Sciences
(LSE:PRM)
Select Model
Select Model
Rating:50Neutral
Price Target:
1.50 p
▼(-5.06% Downside)
Action:Reiterated
Date:07/09/26
The score is held back primarily by weak financial performance—declining revenue, negative gross profit, sustained losses, and a strained balance sheet with high debt and negative equity. Technicals are comparatively supportive (price above major moving averages with positive momentum), but valuation remains challenged due to negative earnings and no dividend data.
Positive Factors
Specialized Proteomics Services
The company operates in a specialized proteomics market and delivers complex analytical workflows that support biomedical research and drug development. Serving pharmaceutical, biotechnology, and academic customers gives the business several end markets and a service offering aligned with ongoing demand for outsourced research capabilities.
Negative Factors
Falling Revenue and Losses
Declining revenue combined with negative gross profit and widening operating and net losses indicates weak cost absorption and limited earnings stability. Persistent losses can constrain investment in laboratory capabilities, reduce strategic flexibility, and make a durable recovery dependent on renewed demand or additional financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Specialized Proteomics Services
The company operates in a specialized proteomics market and delivers complex analytical workflows that support biomedical research and drug development. Serving pharmaceutical, biotechnology, and academic customers gives the business several end markets and a service offering aligned with ongoing demand for outsourced research capabilities.
Read all positive factors
Proteome Sciences (PRM) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£5.10M
Dividend YieldN/A
Average Volume (3M)279.86K
Price to Earnings (P/E)―
Beta (1Y)0.30
Revenue Growth-16.72%
EPS Growth36.28%
CountryUK
Employees32
SectorHealthcare
Sector Strength45
IndustryMedical - Specialties
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding350,724,900
10 Day Avg. Volume195,161
30 Day Avg. Volume279,855
Financial Highlights & Ratios
PEG Ratio0.25
Price to Book (P/B)-0.77
Price to Sales (P/S)1.96
P/FCF Ratio-51.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Proteome Sciences Business Overview & Revenue Model
Company Description
Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally. The company offers TMT LC-MS2, a sta...
How the Company Makes Money
Proteome Sciences primarily makes money by providing fee-for-service proteomics and analytical R&D services to external customers. The core revenue stream is contract revenue from studies where clients pay for experimental design support and execu...
Proteome Sciences Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
26
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.77M | 3.76M | 4.89M | 5.03M | 7.78M | 5.12M |
| Gross Profit | -956.00K | -1.01M | -167.00K | 1.16M | 4.77M | 2.96M |
| EBITDA | -1.30M | -1.74M | -1.52M | -1.14M | 2.13M | 625.00K |
| Net Income | -2.32M | -3.06M | -3.41M | -2.44M | 1.32M | 72.00K |
Balance Sheet | ||||||
| Total Assets | 7.67M | 8.26M | 9.21M | 11.46M | 12.43M | 10.04M |
| Cash, Cash Equivalents and Short-Term Investments | 1.10M | 781.00K | 1.13M | 2.03M | 3.99M | 2.39M |
| Total Debt | 15.95M | 15.77M | 14.52M | 13.47M | 11.91M | 11.69M |
| Total Liabilities | 17.57M | 17.79M | 15.72M | 14.52M | 13.28M | 12.82M |
| Stockholders Equity | -9.90M | -9.53M | -6.52M | -3.07M | -843.00K | -2.77M |
Cash Flow | ||||||
| Free Cash Flow | 367.00K | -143.00K | -1.05M | -718.00K | 2.14B | 8.80B |
| Operating Cash Flow | 425.00K | -46.00K | -826.00K | -481.00K | 3.88B | 10.52B |
| Investing Cash Flow | -56.00K | -97.00K | -224.00K | -424.00K | -21.67B | 4.27B |
| Financing Cash Flow | 461.00K | -204.00K | 151.00K | -1.06M | -209.00K | -400.00K |
Proteome Sciences Technical Analysis
Neutral
1.58
Price Trends
1.60
Negative
1.63
Negative
1.82
Negative
Market Momentum
-0.04
Negative
46.32
Neutral
52.03
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:PRM, the sentiment is Neutral. The current price of 1.58 is above the 20-day moving average (MA) of 1.43, below the 50-day MA of 1.60, and below the 200-day MA of 1.82, indicating a neutral trend. The MACD of -0.04 indicates Negative momentum. The RSI at 46.32 is Neutral, neither overbought nor oversold. The STOCH value of 52.03 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GB:PRM.
Proteome Sciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | £5.10M | -1.99 | 23.85% | ― | -16.72% | 36.28% | |
49 Neutral | £19.27M | -1.10 | -1044.57% | ― | 65.60% | 74.84% | |
48 Neutral | £9.66M | -0.49 | -104.73% | ― | -56.10% | 41.10% | |
47 Neutral | £6.04M | -1.41 | -77.85% | ― | 11.90% | -2864.29% | |
44 Neutral | £5.15M | -0.24 | -138.93% | ― | 77.87% | 84.36% | |
40 Underperform | £5.27M | -0.52 | -481.34% | ― | -10.81% | 42.67% |
* Healthcare Sector Average
GB:PRM
Proteome Sciences
1.45
-0.37
-20.33%
GB:CLBX
ANGLE plc
0.78
-1.98
-71.82%
GB:GDR
Genedrive
1.20
0.97
417.24%
GB:OPTI
OptiBiotix Health
5.85
-5.15
-46.82%
GB:VRCI
Verici Dx Plc
0.23
-0.43
-65.38%
GB:GENI
GENinCode UK Ltd.
0.70
-2.90
-80.56%
Proteome Sciences Corporate Events
Business Operations and StrategyExecutive/Board Changes
Proteome Sciences Adds Former KPMG International CFO Helen Spice to Board
Positive
Sep 16, 2026
Proteome Sciences plc has strengthened its board with the appointment of Helen Spice as an independent non-executive director, effective immediately. Spice, a former CFO of KPMG International and current non-executive director at Barts Health NHS ...
Business Operations and StrategyFinancial Disclosures
Proteome Sciences Builds Order Book as Targeted Proteomics Demand and TMT Sales Rise
Positive
Sep 16, 2026
Proteome Sciences reported interim revenues of £1.87m for the first half of 2026, broadly flat year-on-year, with lower services income offset by stronger TMT reagent sales and royalties, and an improved gross profit thanks to reduced costs. ...
Business Operations and Strategy
Proteome Sciences Wins Major GCLP Chemoproteomics Contract for Global Clinical Trials
Positive
Sep 15, 2026
Proteome Sciences has secured a significant new clinical chemoproteomics contract that will be conducted under Good Clinical Laboratory Practice at its Frankfurt laboratories. The engagement, linked to the same protein studied in two earlier proje...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.